12 Health Care Stocks Moving In Friday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Friday's pre-market session, several healthcare stocks showed significant movement. Avalo Therapeutics (AVTX) led the gainers with a 289.1% increase, while NuCana (NCNA) led the losers with a 21.9% decrease. Other notable movers include Xilio Therapeutics (XLO) and Biodexa Pharmaceuticals (BDRX) with substantial gains, and PAVmed (PAVM) and BioCardia (BCDA) with notable losses.
March 29, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioCardia shares declined by 8.62% to $0.38, with a market value of $9.9 million.
BCDA's stock price drop could be due to investor concerns over clinical trial results or financial health, suggesting a cautious short-term outlook.
CONFIDENCE 65
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
NuCana shares decreased by 21.9% to $0.24, with a market cap of $12.6 million.
The significant drop in NCNA's stock price suggests negative sentiment or disappointing news. This could lead to further declines in the short term as investors reassess the company's value.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
PAVmed stock fell 10.26% to $2.45, with a market cap of $19.7 million.
The decline in PAVM's stock price could reflect market reactions to recent company news or sector trends, potentially leading to further short-term volatility.
CONFIDENCE 70
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
Avalo Therapeutics stock rose 289.1% to $18.48, with a market value of $14.8 million.
The substantial rise in AVTX's stock price indicates strong investor interest, likely due to positive news or developments. This could lead to increased trading volume and potentially more gains in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Biodexa Pharmaceuticals shares moved upwards by 78.11% to $1.53, with a market value of $6.5 million.
BDRX's sharp increase in stock price could indicate investor optimism about the company's pipeline or recent FDA approvals, suggesting potential for further short-term appreciation.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
Xilio Therapeutics stock moved upwards by 205.16% to $1.95, with a market value of $53.6 million.
XLO's significant price increase could be driven by positive clinical trial results or strategic partnerships, leading to heightened investor interest and potential short-term gains.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90